Resverlogix Completes Patient Recruitment for ASSERT Trial
News Feb 08, 2010
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic. At this rate we could be seeing the final dosed patient in May of 2010. In the second half of 2010, we look forward to being able to share the results from the trial, which will mark yet another major milestone in the development of our oral therapeutic for the treatment of atherosclerosis," explained Donald J. McCaffrey, President and CEO of Resverlogix Corp.
Once completed, the randomized, double-blind, placebo-controlled, multi-centered US study will have administered RVX-208 to approximately 280 patients with stable coronary artery disease for a period of 13 weeks. The primary objective of this study is to determine if RVX-208 will produce an increase in plasma apolipoprotein A-I (ApoA-l) levels compared to placebo group after three months of dosing. The secondary objectives are to examine the safety and tolerability of RVX-208, to compare the dose and time response relationships for ApoA-l over time as well as to examine key reverse cholesterol markers involved with HDL functionality.
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019